In these studies, we observed a global increase of CASP3 activation in CRC-SCs subjected to prexasertib-based regimens, and in particular of CASP3A+ cells displaying a DNA content between 2n and 4n (which include premature mitoses) and a 4n DNA content (which include apparent normal mitoses) (Figure 4D). The gene discussed is CASP3; the disease is colorectal carcinoma.